drugset / Trial / NCT00255047

Safety and Immune Response of Different Pediatric Combination Vaccines.

NCT00255047

Phase 3 Completed 2167 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupOpen-labelPrevention

Summary

The overall aim of the study is to corroborate that a schedule consisting of 3 doses of Pentacel™ and a 4th dose of DAPTACEL® and ActHIB® or 4 doses of Pentacel™ or 4 doses of Quadracel and ActHIB® is as safe and immunogenic as a standard of care schedule based on 3 doses of the licensed-equivalent vaccines DAPTACEL®, Vero cell derived Inactivated Poliovirus vaccine (IPOL®), and ActHIB® and a 4th dose of DAPTACEL® and ActHIB®.

Timeline

Start
2005-11
Primary completion
2008-07
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject ActHIB Vaccine 0.5 ml Intramuscular
Subject Adacel Vaccine 0.5 ml Intramuscular
Subject DTaP-IPV Vaccine 0.5 ml Intramuscular
Subject IPOL® Unknown 0.5 ml Intramuscular
Subject Pentacel Vaccine 0.5 ml Intramuscular